• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可溶性晚期糖基化终产物受体与肝癌风险。

Soluble receptor for advanced glycation end products and risk of liver cancer.

机构信息

Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

出版信息

Hepatology. 2013 Jun;57(6):2338-45. doi: 10.1002/hep.26264. Epub 2013 May 14.

DOI:10.1002/hep.26264
PMID:23325627
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3644530/
Abstract

UNLABELLED

Binding of advanced glycation end products (AGEs) to their receptor (RAGE) increases oxidative stress and inflammation and may be involved in liver injury and subsequent carcinogenesis. Soluble RAGE (sRAGE) may neutralize the effects mediated by the AGE/RAGE complex. Epidemiologic studies examining sRAGE or AGEs in association with liver cancer are lacking. We examined the associations between prediagnostic serum concentrations of sRAGE or Nϵ-(carboxymethyl)-lysine (CML)-AGE and hepatocellular carcinoma in a case-cohort study within a cohort of 29,133 Finnish male smokers who completed questionnaires and provided a fasting blood sample between 1985 and 1988. During follow-up beginning 5 years after enrollment through April 2006, 145 liver cancers occurred. Serum concentrations of sRAGE, CML-AGE, glucose, and insulin were measured in case subjects and 485 randomly sampled cohort participants. Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) were available in most cases and in a subset of the study population. Weighted Cox proportional hazards regression was used to calculate relative risks (RR) and 95% confidence intervals (CI) adjusted for age, years of smoking, and body mass index. sRAGE and CML-AGE concentrations were inversely associated with liver cancer. Further adjustment for glucose and insulin or exclusion of case subjects with chronic HBV or HCV did not change the associations.

CONCLUSION

Our results support the hypothesis that sRAGE is inversely associated with liver cancer. The findings need confirmation, particularly in populations that include women and nonsmokers. (HEPATOLOGY 2013 ).

摘要

目的

探讨可溶性晚期糖基化终产物受体(sRAGE)与肝癌的关系。

方法

我们在一项队列研究中对 29133 名芬兰男性吸烟者进行了病例-队列研究,这些吸烟者在 1985 年至 1988 年期间完成了问卷调查并提供了空腹血样。在入组后 5 年开始直至 2006 年 4 月进行随访期间,发生了 145 例肝癌。在病例组和 485 名随机抽样的队列参与者中测量了 sRAGE、CML-AGE、葡萄糖和胰岛素的血清浓度。在大多数病例和研究人群的亚组中均获得了慢性乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)感染的信息。采用加权 Cox 比例风险回归计算了调整年龄、吸烟年限和体重指数后相对危险度(RR)和 95%置信区间(CI)。

结果

sRAGE 和 CML-AGE 浓度与肝癌呈负相关。进一步调整葡萄糖和胰岛素或排除慢性 HBV 或 HCV 的病例组,并未改变这些关联。

结论

我们的结果支持 sRAGE 与肝癌呈负相关的假说。这些发现需要进一步证实,特别是在包括女性和非吸烟者的人群中。

相似文献

1
Soluble receptor for advanced glycation end products and risk of liver cancer.可溶性晚期糖基化终产物受体与肝癌风险。
Hepatology. 2013 Jun;57(6):2338-45. doi: 10.1002/hep.26264. Epub 2013 May 14.
2
Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer.晚期糖基化终产物、晚期糖基化终产物可溶性受体与结直肠癌风险。
Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1430-8. doi: 10.1158/1055-9965.EPI-11-0066. Epub 2011 Apr 28.
3
Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study.证据表明,血清中晚期糖基化终产物可溶性受体水平与胰腺癌风险呈负相关:一项前瞻性研究。
Cancer Res. 2011 May 15;71(10):3582-9. doi: 10.1158/0008-5472.CAN-10-2573. Epub 2011 May 3.
4
Hepatic Fat Content and Liver Enzymes Are Associated with Circulating Free and Protein-Bound Advanced Glycation End Products, Which Are Associated with Low-Grade Inflammation: The CODAM Study.肝脂肪含量和肝酶与循环游离和蛋白结合的晚期糖基化终产物相关,后者与低度炎症相关:CODAM 研究。
J Diabetes Res. 2019 May 14;2019:6289831. doi: 10.1155/2019/6289831. eCollection 2019.
5
Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.循环晚期糖基化终产物可溶性受体与血糖控制及S100A12蛋白呈负相关。
J Clin Endocrinol Metab. 2006 Nov;91(11):4628-34. doi: 10.1210/jc.2005-2559. Epub 2006 Aug 22.
6
Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults.血清中晚期糖基化终产物(AGEs)和 AGEs 的诱饵可溶性受体(sRAGE)的水平可以在年龄、性别和 BMI 匹配的血糖正常成年人中识别非酒精性脂肪性肝病。
Metabolism. 2018 Jun;83:120-127. doi: 10.1016/j.metabol.2018.01.023. Epub 2018 Feb 2.
7
Dietary protein intake and circulating advanced glycation end product/receptor for advanced glycation end product concentrations in the Health, Aging, and Body Composition Study.健康、衰老和身体成分研究中的膳食蛋白质摄入量与循环晚期糖基化终产物/晚期糖基化终产物受体浓度。
Am J Clin Nutr. 2020 Dec 10;112(6):1558-1565. doi: 10.1093/ajcn/nqaa241.
8
AGE-RAGE Interaction Does Not Explain the Clinical Improvements after Therapeutic Fasting in Osteoarthritis.年龄-晚期糖基化终末产物相互作用并不能解释骨关节炎患者治疗性禁食后的临床改善情况。
Complement Med Res. 2018;25(3):167-172. doi: 10.1159/000486237. Epub 2017 Feb 13.
9
A prospective study of soluble receptor for advanced glycation end-products and colorectal cancer risk in postmenopausal women.一项关于可溶性晚期糖基化终产物受体与绝经后妇女结直肠癌风险的前瞻性研究。
Cancer Epidemiol. 2016 Jun;42:115-23. doi: 10.1016/j.canep.2016.04.004. Epub 2016 Apr 18.
10
Activation of the receptor for advanced glycation end products system in women with severe preeclampsia.严重子痫前期妇女晚期糖基化终产物受体系统的激活。
J Clin Endocrinol Metab. 2011 Mar;96(3):689-98. doi: 10.1210/jc.2010-1418. Epub 2011 Feb 16.

引用本文的文献

1
Advanced Glycation End Products in Disease Development and Potential Interventions.疾病发展中的晚期糖基化终末产物及潜在干预措施。
Antioxidants (Basel). 2025 Apr 18;14(4):492. doi: 10.3390/antiox14040492.
2
Comprehensive characterization of differential glycation in hepatocellular carcinoma using tissue proteomics with stable isotopic labeling.利用稳定同位素标记的组织蛋白质组学全面分析肝细胞癌中的差异糖基化。
Anal Bioanal Chem. 2024 Aug;416(20):4531-4541. doi: 10.1007/s00216-024-05392-9. Epub 2024 Jun 26.
3
Prediction of CAF-related genes in immunotherapy and drug sensitivity in hepatocellular carcinoma: a multi-database analysis.预测肝细胞癌免疫治疗和药物敏感性相关的 CAF 基因:多数据库分析。
Genes Immun. 2024 Feb;25(1):55-65. doi: 10.1038/s41435-024-00252-z. Epub 2024 Jan 17.
4
Soluble receptor for advanced glycation end products (sRAGE) is associated with obesity rates: a systematic review and meta-analysis of cross-sectional study.可溶性晚期糖基化终产物受体(sRAGE)与肥胖率有关:一项横断面研究的系统评价和荟萃分析。
BMC Endocr Disord. 2023 Dec 15;23(1):275. doi: 10.1186/s12902-023-01520-1.
5
Nε-(1-Carboxymethyl)-L-lysine, an advanced glycation end product, exerts malignancy on chondrosarcoma via the activation of cancer stemness.Nε-(1-羧甲基)-L-赖氨酸,一种晚期糖基化终产物,通过激活肿瘤干细胞样特性对软骨肉瘤发挥恶性作用。
Arch Toxicol. 2023 Aug;97(8):2231-2244. doi: 10.1007/s00204-023-03539-8. Epub 2023 Jun 14.
6
Effects of AGEs, sRAGE and HMGB1 on Clinical Outcomes in Multiple Myeloma.晚期糖基化终末产物、可溶性晚期糖基化终末产物受体和高迁移率族蛋白B1对多发性骨髓瘤临床结局的影响。
Indian J Hematol Blood Transfus. 2023 Apr;39(2):220-227. doi: 10.1007/s12288-022-01574-6. Epub 2022 Oct 17.
7
Genetically Modified Circulating Levels of Advanced Glycation End-Products and Their Soluble Receptor (AGEs-RAGE Axis) with Risk and Mortality of Breast Cancer.晚期糖基化终末产物及其可溶性受体的基因修饰循环水平(AGEs-RAGE轴)与乳腺癌的风险和死亡率
Cancers (Basel). 2022 Dec 12;14(24):6124. doi: 10.3390/cancers14246124.
8
Circulating and dietary advanced glycation end products and obesity in an adult population: A paradox of their detrimental effects in obesity.循环和饮食中晚期糖基化终产物与成年人肥胖:肥胖中其有害作用的悖论。
Front Endocrinol (Lausanne). 2022 Dec 1;13:966590. doi: 10.3389/fendo.2022.966590. eCollection 2022.
9
RAGE deficiency ameliorates autoimmune hepatitis involving inhibition of IL-6 production via suppressing protein Arid5a in mice.RAGE 缺乏症通过抑制 Arid5a 蛋白减轻了小鼠的自身免疫性肝炎,涉及抑制 IL-6 的产生。
Clin Exp Med. 2023 Oct;23(6):2167-2179. doi: 10.1007/s10238-022-00960-8. Epub 2022 Dec 1.
10
Dietary advanced glycation end products and cancer risk in Japan: From the Takayama study.膳食晚期糖基化终产物与日本癌症风险:来自高山研究。
Cancer Sci. 2022 Aug;113(8):2839-2848. doi: 10.1111/cas.15455. Epub 2022 Jun 25.

本文引用的文献

1
The associations of advanced glycation end products and its soluble receptor with pancreatic cancer risk: a case-control study within the prospective EPIC Cohort.晚期糖基化终产物及其可溶性受体与胰腺癌风险的关联:前瞻性 EPIC 队列内的病例对照研究。
Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):619-28. doi: 10.1158/1055-9965.EPI-11-1139. Epub 2012 Feb 1.
2
Cancer statistics, 2012.癌症统计数据,2012 年。
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.
3
Dietary intake associated with serum versus urinary carboxymethyl-lysine, a major advanced glycation end product, in adults: the Energetics Study.成年人血清与尿羧甲基赖氨酸(一种主要的晚期糖基化终产物)摄入与饮食的相关性:能量学研究。
Eur J Clin Nutr. 2012 Jan;66(1):3-9. doi: 10.1038/ejcn.2011.139. Epub 2011 Jul 27.
4
Fat mass is inversely associated with serum carboxymethyl-lysine, an advanced glycation end product, in adults.在成年人中,脂肪质量与血清羧甲基赖氨酸(一种晚期糖基化终产物)呈负相关。
J Nutr. 2011 Sep;141(9):1726-30. doi: 10.3945/jn.111.143172. Epub 2011 Jul 20.
5
The global epidemiology of hepatocellular carcinoma: present and future.肝细胞癌的全球流行病学:现状与未来。
Clin Liver Dis. 2011 May;15(2):223-43, vii-x. doi: 10.1016/j.cld.2011.03.006.
6
Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study.证据表明,血清中晚期糖基化终产物可溶性受体水平与胰腺癌风险呈负相关:一项前瞻性研究。
Cancer Res. 2011 May 15;71(10):3582-9. doi: 10.1158/0008-5472.CAN-10-2573. Epub 2011 May 3.
7
Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer.晚期糖基化终产物、晚期糖基化终产物可溶性受体与结直肠癌风险。
Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1430-8. doi: 10.1158/1055-9965.EPI-11-0066. Epub 2011 Apr 28.
8
What is the role of the receptor for advanced glycation end products-ligand axis in liver injury?晚期糖基化终产物受体-配体轴在肝损伤中的作用是什么?
Liver Transpl. 2011 Jun;17(6):633-40. doi: 10.1002/lt.22306.
9
Hepatocellular cancer in the non-cirrhotic liver.非肝硬化肝脏中的肝细胞癌。
J Visc Surg. 2011 Feb;148(1):3-11. doi: 10.1016/j.jviscsurg.2010.12.012.
10
Is HMGB1 a new indirect marker for revealing fibrosis in chronic hepatitis and a new therapeutic target in treatment?HMGB1 是否是一种揭示慢性肝炎纤维化的新间接标志物,以及一种新的治疗靶点?
Viral Immunol. 2010 Dec;23(6):633-8. doi: 10.1089/vim.2010.0080.